Statins And Interstitial Lung Abnormalities In Smokers

G. R. Washko¹, H. Hatabu¹, I. Fernandez¹, M. Nishino¹, Y. Okajima¹, T. Yamashiro¹, J. Ross¹, R. Estepar¹, A. Diaz², B. Himes³, C. Come¹, K. D’Aco¹, F. J. Martinez⁴, M. K. Han⁵, D. A. Lynch⁶, J. Crapo⁷, E. K. Silverman⁸, I. O. Rosas⁸, G. M. Hunninghake¹, and the COPDGene Investigators

¹Brigham and Women’s Hospital, Boston, MA, ²Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ³Brigham and Women’s Hospital, Boston, ⁴University of Arizona, Tucson, AZ, ⁵University of Michigan, Ann Arbor, MI, ⁶National Jewish Health Center, Denver, CO, ⁷National Jewish Health, Denver, CO, ⁸Brigham & Women’s Hospital, Boston, MA

Corresponding author’s email: ghunninghake@partners.org

Rationale: HMG-CoA reductase inhibitors (statins) have been implicated in the development of interstitial lung disease (ILD) but the relationship between statins and interstitial lung abnormalities (ILA) in smokers has not been assessed.

Methods: We used logistic regression analysis to evaluate the association between statin use and ILA in 2,115 (84%) of the first 2,508 subjects in COPDGene for whom a chest computed tomogram (CT) and information about medication use was available for analysis.

Results: In COPDGene, 38% of subjects with ILA were taking statins compared to 27% of subjects without ILA. Statin use was positively associated with ILA (odds ratio [OR] 1.60, 95% confidence interval [CI] 1.03-2.50, P=0.04) after adjustment for covariates including a history of high cholesterol. The risk of ILA was higher in subjects on hydrophilic statins (OR 3.43, 95% CI 1.68-7.01, P<0.001) than in subjects on lipophilic statins (OR 1.36, 95% CI 0.87-2.14, P=0.18). Statin use was associated with radiologic features of pulmonary fibrosis (e.g., statin users were ~125% more likely to have traction bronchiectasis, OR 2.25, 95% CI, 1.33-3.83, P=0.003). The association between statin use and ILA was also modified by age (in subjects > 65 years old, statin users were 96% more likely to have ILA, OR 1.96, 95% CI 1.06-3.61, P=0.03).

Conclusions: Statin use is associated with ILA among smokers in the COPDGene study. The low reported incidence of statin-associated ILD in clinical practice suggests that either the progression of ILA to overt clinical disease is variable or this condition is underrecognized.

This abstract is funded by: Support: COPDGene is supported by NIH Grant Numbers U01 HL089897 and U01 HL089856. G.R.W. is supported by NIH Grant Number: K23 HL089353 and an award from the Parker B. Francis Foundation. H.H. is support by NIH Grant Number: 5R21CA116271-2. B.E.H. is supported by 2T15LM007092-16 from the National Library of Medicine. I.O.R. is supported by NIH Grant Number K23 HL087030. G.M.H. is supported by NIH grant: K08 HL092222.

Am J Respir Crit Care Med 185;2012:A5170
Internet address: www.atsjournals.org